No data
Share
Bortezomib
Category:
Summary:
CAS:
Standard:
Purity:
Keywords:
API and Intermediates
- Product description
-
Product Intro
Bortezomib is a new antitumor drug developed by Millennium pharmaceutical company of the United States. The drug is a 26S proteasome inhibitor, which leads to the death of tumor cells by blocking the degradation of a variety of proteins regulating apoptosis and signal transduction in cells. A large number of studies have found that bortezomib has strong antitumor activity against a variety of tumors, especially multiple myeloma, mantle cell lymphoma and other B-cell lymphoma (diffuse large B-cell type, follicular cell type, small lymphocytic / chronic lymphocytic leukemia, limbic lymphoma) and Hodgkin lymphoma.
FunctionBortezomib is a reversible inhibitor of chymotrypsin like activity of 26S proteasome in mammalian cells. The inhibition of 26S proteasome can prevent the hydrolysis of specific protein. Preclinical tumor model in vivo trials have shown that bortezomib can delay tumor growth, including multiple myeloma.
Application
This product is used for the treatment of patients with multiple myeloma. This patient has received at least two treatments before using this product, and his condition is still progressing in the latest treatment. The effectiveness of this product is based on its efficiency. No clinical controlled trials have demonstrated its clinical benefits, such as improved survival.
Previous page
Next page
Previous page
Next page
Messages
Note: Please provide accurate and detailed information, and our professional staff will contact you as soon as possible!
Recommended products